Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Furiex Pharmaceuticals, Inc. (FURX)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 0.0% | 0.0% | 0.0% | 0.2% | 4.2% | 0.8% |
| Gross profit | 100.0% | 100.0% | 100.0% | 99.8% | 95.8% | 99.2% |
| Selling, general and administrative | 17.9% | 27.8% | 195.1% | 92.0% | 40.4% | 9.4% |
| Research and development | 116.5% | 171.6% | 984.5% | 557.9% | 186.9% | 43.7% |
| EBITDA | -34.3% | -99.4% | -1079.6% | -551.3% | -131.6% | 53.2% |
| Depreciation | 0.1% | 0.2% | 1.8% | | | 7.7% |
| EBIT | -34.4% | -99.6% | -1081.4% | -551.3% | -131.6% | 45.5% |
| Pre-tax income | -41.3% | -105.8% | -1090.6% | -551.2% | -131.5% | 36.9% |
| Income taxes | 0.5% | 0.0% | 0.3% | 0.2% | 10.0% | 0.0% |
| Net income | -41.8% | -105.8% | -1090.9% | -608.5% | -141.5% | 31.6% |
|